HRP20170557T2 - Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 - Google Patents

Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 Download PDF

Info

Publication number
HRP20170557T2
HRP20170557T2 HRP20170557TT HRP20170557T HRP20170557T2 HR P20170557 T2 HRP20170557 T2 HR P20170557T2 HR P20170557T T HRP20170557T T HR P20170557TT HR P20170557 T HRP20170557 T HR P20170557T HR P20170557 T2 HRP20170557 T2 HR P20170557T2
Authority
HR
Croatia
Prior art keywords
fibrosis
compound
preparation according
kidney
disease
Prior art date
Application number
HRP20170557TT
Other languages
English (en)
Croatian (hr)
Inventor
Balkrishen Bhat
Original Assignee
Regulus Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc. filed Critical Regulus Therapeutics Inc.
Publication of HRP20170557T1 publication Critical patent/HRP20170557T1/hr
Publication of HRP20170557T2 publication Critical patent/HRP20170557T2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
HRP20170557TT 2011-04-25 2012-04-25 Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21 HRP20170557T2 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity
EP12718549.4A EP2702155B9 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Publications (2)

Publication Number Publication Date
HRP20170557T1 HRP20170557T1 (hr) 2017-06-16
HRP20170557T2 true HRP20170557T2 (hr) 2020-02-21

Family

ID=46025979

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170557TT HRP20170557T2 (hr) 2011-04-25 2012-04-25 Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21
HRP20210616TT HRP20210616T1 (hr) 2011-04-25 2021-04-19 Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210616TT HRP20210616T1 (hr) 2011-04-25 2021-04-19 Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21

Country Status (30)

Country Link
US (7) US9181547B2 (enExample)
EP (3) EP2702155B9 (enExample)
JP (2) JP6320292B2 (enExample)
KR (2) KR20190063482A (enExample)
CN (3) CN113151272A (enExample)
AU (4) AU2012249851B2 (enExample)
BR (1) BR112013027187A2 (enExample)
CA (2) CA2833615C (enExample)
CL (1) CL2013003105A1 (enExample)
CO (1) CO6821889A2 (enExample)
CY (1) CY1120304T1 (enExample)
DK (2) DK2702155T3 (enExample)
EA (1) EA025894B1 (enExample)
ES (2) ES2868950T3 (enExample)
HR (2) HRP20170557T2 (enExample)
HU (2) HUE054129T2 (enExample)
IL (3) IL229032B (enExample)
LT (2) LT2702155T (enExample)
MX (5) MX393138B (enExample)
MY (2) MY187685A (enExample)
NZ (1) NZ717921A (enExample)
PH (1) PH12013502199A1 (enExample)
PL (2) PL3211082T3 (enExample)
PT (2) PT3211082T (enExample)
RS (1) RS61775B1 (enExample)
SG (1) SG194636A1 (enExample)
SI (2) SI3211082T1 (enExample)
TW (2) TWI698445B (enExample)
UA (1) UA115652C2 (enExample)
WO (1) WO2012148952A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
DK2702155T3 (en) * 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
US9193971B2 (en) * 2012-04-10 2015-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of nonalcoholic steatohepatitis
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
FI3684949T3 (fi) 2017-09-22 2024-07-17 Univ Washington Solumolekyylien kombinatorinen in situ -leimaaminen
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) * 2025-07-15 2025-08-19 湖南工程学院 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296262B6 (cs) 1998-05-22 2006-02-15 Boys Town National Research Hospital Farmaceutický prostredek
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
WO2006020768A2 (en) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
JP2008512463A (ja) 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1959012A3 (en) 2004-12-29 2009-12-30 Exiqon A/S Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
DK1931780T3 (en) * 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
MX2008012219A (es) 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
ES2569558T3 (es) * 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
WO2008042973A2 (en) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
US8906870B2 (en) 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2118118B1 (en) 2007-01-19 2017-09-27 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
JP5535076B2 (ja) * 2007-10-29 2014-07-02 レグルス・セラピューティクス・インコーポレイテッド 肝臓癌を治療するための標的化ミクロｒｎａ
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
JP2011510678A (ja) 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
CA2753562A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
US20120148664A1 (en) 2009-06-08 2012-06-14 Miragen Therapeutics Chemical modifications motifs for mirna inhibitors and mimetics
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
DK2702155T3 (en) 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CA2886116C (en) 2012-09-26 2022-06-07 Mirrx Therapeutics Oligomers with improved off-target profile
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
WO2012148952A1 (en) 2012-11-01
AU2020201403A1 (en) 2020-03-12
DK3211082T3 (da) 2021-05-10
CN113249381A (zh) 2021-08-13
TWI607016B (zh) 2017-12-01
TW201300404A (zh) 2013-01-01
US20120270928A1 (en) 2012-10-25
IL273381A (en) 2020-05-31
AU2012249851A1 (en) 2013-10-31
AU2017219156A1 (en) 2017-09-21
UA115652C2 (uk) 2017-12-11
LT2702155T (lt) 2017-05-10
US20200291400A1 (en) 2020-09-17
PT3211082T (pt) 2021-04-28
EP2702155B9 (en) 2020-01-01
AU2012249851A8 (en) 2013-11-14
US12331294B2 (en) 2025-06-17
US8912161B2 (en) 2014-12-16
EP3933040A1 (en) 2022-01-05
CA2833615A1 (en) 2012-11-01
JP2014518619A (ja) 2014-08-07
ES2868950T3 (es) 2021-10-22
EA201391492A1 (ru) 2014-04-30
KR20140033062A (ko) 2014-03-17
DK2702155T3 (en) 2017-05-01
ES2621863T3 (es) 2017-07-05
EP3211082A1 (en) 2017-08-30
US20160138016A1 (en) 2016-05-19
LT3211082T (lt) 2021-05-10
EA025894B1 (ru) 2017-02-28
CY1120304T1 (el) 2019-07-10
KR20190063482A (ko) 2019-06-07
US20140329887A1 (en) 2014-11-06
TW201811812A (zh) 2018-04-01
CA2833615C (en) 2022-08-30
CL2013003105A1 (es) 2014-08-01
US20220098583A1 (en) 2022-03-31
SG194636A1 (en) 2013-12-30
ES2621863T9 (es) 2020-02-13
PH12013502199A1 (en) 2014-01-27
HRP20210616T1 (hr) 2021-05-28
MY187685A (en) 2021-10-11
RS61775B1 (sr) 2021-05-31
KR102055172B1 (ko) 2020-01-23
JP2018121646A (ja) 2018-08-09
EP3211082B1 (en) 2021-02-17
AU2022203067A1 (en) 2022-05-26
PT2702155T (pt) 2017-04-03
CO6821889A2 (es) 2013-12-31
JP6320292B2 (ja) 2018-05-09
MX2022000212A (es) 2022-04-01
CA3165397A1 (en) 2012-11-01
PL3211082T3 (pl) 2021-08-02
US20140107183A1 (en) 2014-04-17
MX2022006595A (es) 2022-07-01
PL2702155T3 (pl) 2017-09-29
BR112013027187A2 (pt) 2017-06-06
MY175336A (en) 2020-06-19
US9181547B2 (en) 2015-11-10
MX2019003090A (es) 2019-07-18
HRP20170557T1 (hr) 2017-06-16
HK1243130A1 (en) 2018-07-06
US9790496B2 (en) 2017-10-17
IL229032A0 (en) 2013-12-31
CN103620035A (zh) 2014-03-05
MX393138B (es) 2025-03-24
EP2702155A1 (en) 2014-03-05
AU2012249851B2 (en) 2017-06-08
MX2013012452A (es) 2014-11-21
SI3211082T1 (sl) 2021-08-31
AU2017219156B2 (en) 2020-01-02
EP2702155B1 (en) 2017-02-01
HUE031595T2 (en) 2017-07-28
NZ616748A (en) 2016-03-31
MX2019003089A (es) 2019-07-18
TWI698445B (zh) 2020-07-11
IL229032B (en) 2021-01-31
CN103620035B (zh) 2021-04-23
US20180155719A1 (en) 2018-06-07
IL266529A (en) 2019-07-31
SI2702155T1 (sl) 2017-07-31
CN113151272A (zh) 2021-07-23
HUE054129T2 (hu) 2021-08-30
NZ717921A (en) 2017-09-29

Similar Documents

Publication Publication Date Title
HRP20170557T2 (hr) Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21
JP2015519891A5 (enExample)
JP2014518619A5 (enExample)
RU2020113612A (ru) Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
Paulis et al. Novel therapeutic targets for hypertension
WO2009044392A3 (en) Novel sirna structures
EA201070992A1 (ru) МИКРО-РНК (miРНК) И МИШЕНИ СИГНАЛЬНОГО ПУТИ ДЛЯ ДИАГНОСТИЧЕСКИХ И ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ
RU2018129378A (ru) Способ лечения с3-гломерулопатии
EP2446036A4 (en) TREATMENT OF ILLNESSES ASSOCIATED WITH TUMORNEKROSE FACTOR RECEPTOR 2 (TNFR2) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST TNFR2
RU2015110979A (ru) Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2009025763A3 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2011028609A3 (en) Devices and methods for using controlled bubble cloud cavitation in fractionating urinary stones
WO2012177481A3 (en) Fibroblast growth factor receptor inhibition for the treatment of disease
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
JP2013506684A5 (enExample)
PH12014500943A1 (en) Combination treatment of cancer
WO2006086456A3 (en) Combination of organic compounds
RU2013114365A (ru) Лечение инфаркта миокарда с использованием антагонистов tgf-бета
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
NZ603602A (en) Compositions and methods for treatment of kidney disorders
JP2016512817A5 (enExample)
PH12013500559A1 (en) Combination therapy for treating hcv infection
RU2017104111A (ru) Ингибиторы внешнего медуллярного калиевого канала